Do analysts rate APVO or GNTA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, APVO or GNTA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptevo Therapeutics N/A N/A -$25.97M -$197.60 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Is APVO or GNTA more profitable?

Genenta Science's return on equity of 0.00% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -198.50% -117.06% Genenta Science N/A N/A N/A

Do analysts recommend APVO or JSPR?

Jasper Therapeutics has a consensus target price of $13.14, suggesting a potential upside of 2,720.36%. Given Jasper Therapeutics' higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Aptevo Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Jasper Therapeutics 1 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher valuation and earnings, APVO or JSPR?

Jasper Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptevo Therapeutics N/A N/A -$25.97M -$197.60 N/A Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A

Is APVO or JSPR more profitable?

Aptevo Therapeutics' return on equity of -198.50% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -198.50% -117.06% Jasper Therapeutics N/A -613.51% -162.52%

Do analysts recommend VYNE or APVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Do analysts prefer TPST or APVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has preferable earnings & valuation, TPST or APVO?

Tempest Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A Aptevo Therapeutics N/A N/A -$25.97M -$197.60 N/A

Is TPST or APVO more profitable?

Aptevo Therapeutics' return on equity of -198.50% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% Aptevo Therapeutics N/A -198.50% -117.06%

Do analysts rate APVO or NXTC?

NextCure has a consensus price target of $23.00, suggesting a potential upside of 887.12%. Given NextCure's higher possible upside, analysts plainly believe NextCure is more favorable than Aptevo Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 NextCure 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has better earnings & valuation, APVO or NXTC?

NextCure is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptevo Therapeutics N/A N/A -$25.97M -$197.60 N/A NextCure N/A N/A -$55.84M -$17.19 N/A

Is APVO or NXTC more profitable?

NextCure's return on equity of -186.96% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -198.50% -117.06% NextCure N/A -186.96% -124.62%

Aptevo Therapeutics (APVO) Competitors

$4.76 -0.13 (-2.66%)

Closing price 04:00 PM Eastern

Extended Trading

$4.84 +0.08 (+1.58%)

As of 06:18 PM Eastern

Compare

APVO vs. GNTA, JSPR, VYNE, TPST, and NXTC

Should you buy Aptevo Therapeutics stock or one of its competitors? MarketBeat compares Aptevo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aptevo Therapeutics include Genenta Science (GNTA), Jasper Therapeutics (JSPR), VYNE Therapeutics (VYNE), Tempest Therapeutics (TPST), and NextCure (NXTC). These companies are all part of the "pharmaceutical products" industry.

How does Aptevo Therapeutics compare to Genenta Science?

Aptevo Therapeutics (NASDAQ:APVO) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Genenta Science's return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-198.50%	-117.06%
Genenta Science	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 0.1% of Aptevo Therapeutics shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aptevo Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market. Comparatively, Genenta Science has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

In the previous week, Genenta Science had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 2 mentions for Genenta Science and 1 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 1.89 beat Genenta Science's score of 0.43 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aptevo Therapeutics	Very Positive
Genenta Science	Neutral

Summary

Genenta Science beats Aptevo Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Jasper Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 0.1% of Aptevo Therapeutics shares are owned by insiders. Comparatively, 4.6% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Jasper Therapeutics had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 2 mentions for Jasper Therapeutics and 1 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 1.89 beat Jasper Therapeutics' score of 0.47 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aptevo Therapeutics	Very Positive
Jasper Therapeutics	Neutral

Jasper Therapeutics has a consensus target price of $13.14, suggesting a potential upside of 2,720.36%. Given Jasper Therapeutics' higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Jasper Therapeutics	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Aptevo Therapeutics' return on equity of -198.50% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-198.50%	-117.06%
Jasper Therapeutics	N/A	-613.51%	-162.52%

Aptevo Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3, indicating that its share price is 200% more volatile than the broader market.

Jasper Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A

Summary

Jasper Therapeutics beats Aptevo Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Aptevo Therapeutics compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aptevo Therapeutics has lower revenue, but higher earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	39.24	-$26.48M	-$0.38	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, VYNE Therapeutics and VYNE Therapeutics both had 1 articles in the media. VYNE Therapeutics' average media sentiment score of 1.89 equaled Aptevo Therapeutics'average media sentiment score.

Company	Overall Sentiment
VYNE Therapeutics	Very Positive
Aptevo Therapeutics	Very Positive

VYNE Therapeutics has a beta of 2, meaning that its share price is 100% more volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market.

Aptevo Therapeutics has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

Summary

VYNE Therapeutics beats Aptevo Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

Aptevo Therapeutics' return on equity of -198.50% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are held by institutional investors. 6.3% of Tempest Therapeutics shares are held by insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Tempest Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A

In the previous week, Tempest Therapeutics had 2 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 3 mentions for Tempest Therapeutics and 1 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 1.89 beat Tempest Therapeutics' score of 1.28 indicating that Aptevo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Tempest Therapeutics	Positive
Aptevo Therapeutics	Very Positive

Tempest Therapeutics has a beta of -1.85, meaning that its stock price is 285% less volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market.

Summary

Aptevo Therapeutics beats Tempest Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Aptevo Therapeutics compare to NextCure?

Aptevo Therapeutics (NASDAQ:APVO) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

NextCure's return on equity of -186.96% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-198.50%	-117.06%
NextCure	N/A	-186.96%	-124.62%

Aptevo Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, NextCure has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

In the previous week, NextCure had 2 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 3 mentions for NextCure and 1 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 1.89 beat NextCure's score of 0.03 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aptevo Therapeutics	Very Positive
NextCure	Neutral

NextCure is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

NextCure has a consensus price target of $23.00, suggesting a potential upside of 887.12%. Given NextCure's higher possible upside, analysts plainly believe NextCure is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
NextCure	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 0.1% of Aptevo Therapeutics shares are owned by company insiders. Comparatively, 11.9% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Aptevo Therapeutics and NextCure tied by winning 7 of the 14 factors compared between the two stocks.

Get Aptevo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APVO vs. The Competition

Export

Metric	Aptevo Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.09M	$3.30B	$6.64B	$12.06B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-0.02	10.40	20.93	22.06
Price / Sales	N/A	297.55	508.64	105.22
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	0.27	8.06	10.47	6.72
Net Income	-$25.97M	$23.83M	$3.56B	$337.35M
7 Day Performance	-5.56%	-2.82%	-1.11%	-2.54%
1 Month Performance	-4.23%	2.22%	1.28%	1.42%
1 Year Performance	-94.35%	37.70%	21.20%	24.71%

Aptevo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APVO Aptevo Therapeutics	1.8808 of 5 stars	$4.76 -2.7%	N/A	-94.5%	$6.09M	N/A	N/A	50	Positive News
GNTA Genenta Science	0.2435 of 5 stars	$1.03 +15.1%	N/A	-64.1%	$24.30M	N/A	N/A	7	Short Interest Increase Gap Down
JSPR Jasper Therapeutics	2.4597 of 5 stars	$0.83 -6.9%	$13.14 +1,485.4%	-92.2%	$23.21M	N/A	N/A	20	News Coverage
VYNE VYNE Therapeutics	1.4833 of 5 stars	$0.68 -0.7%	N/A	-34.1%	$22.74M	$570K	N/A	30	Positive News
TPST Tempest Therapeutics	2.7683 of 5 stars	$1.53 -11.6%	N/A	-84.6%	$22.65M	N/A	N/A	20	Positive News Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APVO) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptevo Therapeutics (APVO) Competitors

APVO vs. GNTA, JSPR, VYNE, TPST, and NXTC

How does Aptevo Therapeutics compare to Genenta Science?

Summary

How does Aptevo Therapeutics compare to Jasper Therapeutics?

Summary

How does Aptevo Therapeutics compare to VYNE Therapeutics?

Summary

How does Aptevo Therapeutics compare to Tempest Therapeutics?

Summary

How does Aptevo Therapeutics compare to NextCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO vs. The Competition

Aptevo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptevo Therapeutics (APVO) Competitors

APVO vs. GNTA, JSPR, VYNE, TPST, and NXTC

How does Aptevo Therapeutics compare to Genenta Science?

Is APVO or GNTA more profitable?

Which has higher earnings & valuation, APVO or GNTA?

Do institutionals & insiders hold more shares of APVO or GNTA?

Do analysts rate APVO or GNTA?

Which has more risk & volatility, APVO or GNTA?

Does the media prefer APVO or GNTA?

Summary

How does Aptevo Therapeutics compare to Jasper Therapeutics?

Do institutionals and insiders hold more shares of APVO or JSPR?

Does the media prefer APVO or JSPR?

Do analysts recommend APVO or JSPR?

Is APVO or JSPR more profitable?

Which has more volatility and risk, APVO or JSPR?

Which has higher valuation and earnings, APVO or JSPR?

Summary

How does Aptevo Therapeutics compare to VYNE Therapeutics?

Do insiders and institutionals have more ownership in VYNE or APVO?

Which has better valuation and earnings, VYNE or APVO?

Do analysts recommend VYNE or APVO?

Does the media favor VYNE or APVO?

Which has more volatility & risk, VYNE or APVO?

Is VYNE or APVO more profitable?

Summary

How does Aptevo Therapeutics compare to Tempest Therapeutics?

Is TPST or APVO more profitable?

Do insiders & institutionals have more ownership in TPST or APVO?

Do analysts prefer TPST or APVO?

Which has preferable earnings & valuation, TPST or APVO?

Does the media refer more to TPST or APVO?

Which has more risk and volatility, TPST or APVO?

Summary

How does Aptevo Therapeutics compare to NextCure?

Is APVO or NXTC more profitable?

Which has more risk and volatility, APVO or NXTC?

Does the media prefer APVO or NXTC?

Which has better earnings & valuation, APVO or NXTC?

Do analysts rate APVO or NXTC?

Do institutionals and insiders hold more shares of APVO or NXTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO vs. The Competition

Aptevo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools